



# SIDDS 2022

**Seoul International Digestive Disease Symposium 2022**

*In conjunction with the annual meeting of Korean Society of Gastroenterology*

**April 16-17, 2022 Virtual Congress**



Name	Hee Seung Lee
Affiliation	Yonsei University College of Medicine
Country	South Korea
Major Field	Pancreatic cancer, Cholangiocarcinoma

## Educational Background

2007.2: Yonsei University College of Medicine, bachelor's degree  
2017.2: Yonsei University College of Medicine, M.D, Ph.D.

## Professional Experience

2007.3~2008.2: Internship, Yonsei University Health System, Seoul, Korea  
2011.3~2015.2: Residency in Internal Medicine. Severance Hospital, Yonsei University Health System, Seoul, Korea  
2015.3~2016.2: Fellowship, Yonsei University Health System, Seoul, Korea  
2016.3~2018.2: Clinical research assistant professor  
2018.3~Present: Clinical assistant professor

## Other Experience and Professional Memberships

Member of the Korean Society of Pancreas and Biliary Tract  
Member of the Korean Society of Gastrointestinal Cancer  
Member of the Korean Association of Internal Medicine  
Member of the Korean Society of Gastroenterology  
Member of the Korean Society of Gastrointestinal Endoscopy

## Main Scientific Publications (First author or corresponding author)

- (1) BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients, *Cancers* 2022
- (2) Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial, *Ther Adv Med Oncol*, 2021
- (3) Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. *EBioMedicine*, 2021
- (4) Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma, *Cancers*, 2021
- (5) Usefulness of Smartphone Applications for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial, *JMIR mHealth and uHealth*, 2021
- (6) Establishment of primary pancreatic cancer cell lines with endoscopic ultrasound-guided fine needle biopsy via conditionally reprogrammed cell culture. *Cancer medicine*, 2018



# SIDDS 2022

**Seoul International Digestive Disease Symposium 2022**

*In conjunction with the annual meeting of Korean Society of Gastroenterology*

**April 16-17, 2022 Virtual Congress**



(7) Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer, Scientific reports. 2018

(8) A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Scientific reports. 2017

(9) Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer. Gastrointest Endosc. 2017